Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
10.86
-0.01 (-0.09%)
At close: Feb 12, 2026, 4:00 PM EST
10.71
-0.15 (-1.38%)
Pre-market: Feb 13, 2026, 7:06 AM EST
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 45 employees as of December 31, 2024. The number of employees decreased by 31 or -40.79% compared to the previous year.
Employees
45
Change (1Y)
-31
Growth (1Y)
-40.79%
Revenue / Employee
n/a
Profits / Employee
-$1,580,311
Market Cap
716.44M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 45 | -31 | -40.79% |
| Dec 31, 2023 | 76 | -13 | -14.61% |
| Dec 31, 2022 | 89 | -15 | -14.42% |
| Dec 31, 2021 | 104 | 31 | 42.47% |
| Dec 31, 2020 | 73 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Gyre Therapeutics | 579 |
| Arvinas | 430 |
| KalVista Pharmaceuticals | 270 |
| Kura Oncology | 192 |
| Cullinan Therapeutics | 111 |
| AgomAb Therapeutics NV | 58 |
FULC News
- 6 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - Benzinga
- 2 months ago - Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript - Seeking Alpha
- 2 months ago - Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire